United Therapeutics (UTHR) Tops Q2 EPS by 24c
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $487.61 --0%
Revenue Growth %: -1.2%
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -1.2%
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.55, $0.24 better than the analyst estimate of $2.31. Revenue for the quarter came in at $347.2 million versus the consensus estimate of $360.41 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- Citi upgrades C.H. Robinson to Buy with $185 target, Opens 90-Day upside catalyst watch
- Barclays Downgrades Ipsen SA (IPN:FP) (IPSEF) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
